12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adempas riociguat: Additional Phase III data

Additional data from the double-blind, international Phase III CHEST-1 trial in 261 patients with inoperable CTEPH or with persistent or recurrent pulmonary hypertension after pulmonary endarterectomy showed that thrice-daily oral riociguat significantly reduced PVR by 226 dyne*sec/cm5 vs. a 23 dyne*sec/cm5 increase for placebo (p<0.001). Riociguat also significantly reduced NT-proBNP levels by 291 pg/mL vs. a 76 pg/mL increase for...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >